Filing Details

Accession Number:
0001104659-19-068397
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-27 19:00:20
Reporting Period:
2019-11-25
Accepted Time:
2019-11-27 19:00:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc. ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559569 Mark Pruzanski C/O Intercept Pharmaceuticals, Inc.
10 Hudson Yards, Floor 37
New York NY 10001
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-11-25 39 $8.67 469,165 No 4 M Direct
Common Stock Acquisiton 2019-11-25 14,524 $8.67 483,689 No 4 M Direct
Common Stock Disposition 2019-11-25 14,563 $100.00 469,126 No 4 S Direct
Common Stock Acquisiton 2019-11-26 19,880 $8.67 489,006 No 4 M Direct
Common Stock Acquisiton 2019-11-26 15,557 $21.50 504,563 No 4 M Direct
Common Stock Disposition 2019-11-26 35,437 $100.00 469,126 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock Disposition 2019-11-25 39 $0.00 39 $8.67
Common Stock Option to Purchase Common Stock Disposition 2019-11-25 14,524 $0.00 14,524 $8.67
Common Stock Option to Purchase Common Stock Disposition 2019-11-26 19,880 $0.00 19,880 $8.67
Common Stock Option to Purchase Common Stock Disposition 2019-11-26 15,557 $0.00 15,557 $21.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-08-16 No 4 M Direct
19,880 2021-10-13 No 4 M Direct
0 2021-10-13 No 4 M Direct
30,601 2022-11-16 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 100,000 Indirect By GRAT
Footnotes
  1. This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
  2. This option is fully vested and exercisable.
  3. This option is fully vested and exercisable.
  4. This option is fully vested and exercisable.